Ivabradina Aurovitas (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. Inhibiting this current slows the spontaneous depolarisation of pacemaker cells, resulting in a lower heart rate without decreasing the strength of cardiac contraction or blood pressure.

The dose of Ivabradina Aurovitas is determined by the prescribing clinician based on the patient’s clinical condition, heart‑rate response, and tolerance. Dosage adjustments are made according to therapeutic goals and any concomitant medications, following local prescribing guidelines.

Safety data for ivabradine in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on adrenergic receptors and can reduce contractile force and blood pressure, which may be undesirable in some patients. Ivabradine is often considered when beta‑blockers are contraindicated or not tolerated.

Store Ivabradina Aurovitas at temperatures below 25 °C in its original container. Protect the tablets from moisture, direct sunlight and excessive heat to maintain stability and potency throughout the shelf‑life.

Ivabradina Aurovitas is taken orally, usually with a glass of water. The tablet should be swallowed whole and not split, crushed, or chewed, unless the prescribing information specifically allows it. Dosing times are generally spaced evenly to maintain consistent heart‑rate control.

The most serious adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, persistent visual disturbances, and rare cases of hepatic dysfunction or severe allergic reactions. Patients should be monitored for these events, especially when initiating therapy or adjusting doses.

Ivabradina Aurovitas should be avoided in patients with severe hepatic impairment, uncontrolled hypotension, acute decompensated heart failure, or those with a resting heart rate below 50 bpm before treatment. It is also contraindicated in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment.